Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain

Journal of Supportive Oncology

Volumn 4, Issue 10, 2006, Pages 531-535

  Sutton, Ian R ^a   Daeninck, Paul ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALIZAPRIDE; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; APREPITANT; CANNABINOID DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CISPLATIN; DEXAMETHASONE; DOMPERIDONE; DRONABINOL; FENTANYL; GABAPENTIN; GEMCITABINE; GRANISETRON; HALOPERIDOL; HYDROMORPHONE; HYPNOTIC AGENT; LEVONANTRADOL; METOCLOPRAMIDE; MORPHINE; NABILONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PLACEBO; PROCHLORPERAZINE; PSYCHEDELIC AGENT; SEDATIVE AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMAL THINKING; ADJUVANT THERAPY; ALLODYNIA; ANALGESIA; ARTICLE; ATAXIA; ATTENTION DISTURBANCE; BREAST CANCER; CANCER PAIN; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG WITHDRAWAL; EUPHORIA; FAMILY HISTORY; HUMAN; HYPERALGESIA; INTRACTABLE PAIN; LOW DRUG DOSE; LUNG CANCER; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN ASSESSMENT; PARANOIA; POSTOPERATIVE PAIN; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; VERTIGO; XEROSTOMIA;

AGED; ANTINEOPLASTIC AGENTS; CANNABINOIDS; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; VOMITING;

EID: 33846280125     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society; 2006.
3. Berger AM, Portenoy RK, Weissman DE, eds. Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven; 1998.
4. Wiser W, Berger A. Practical management of chemotherapy-induced nausea and vomiting. Oncology 2005;19:637-645.
5. Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. 2nd ed. Baltimore, MD. The Johns Hopkins University Press; 2005.
6. World Health Organization. Global cancer rates could increase by 50% to 15 million by 2020. April 3, 2003. Available at: http://www.who.int/ mediacentre/news/releases/2003/pr27/en/. Accessed October 19, 2006.
7. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-1132.
8. Khatcheressian J, Cassel JB, Lyckholm L, et al. Improving palliative and supportive care in cancer patients. Oncology 2005;19:1365-1376.
9. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098.
10. Brames MJ, Cullen MT, Einhorn LH. Efficacy and safety of multiple-day palonosetron (PALO) with dexamethasone (DEX) for prevention of CINV in patients receiving 5-day cisplatin-based regimens for germ cell cancer. Presented at the MASCC/ISOO 18th International Symposium; June 22-24,2006; Toronto, Canada. Abstract 04-027.
11. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003;11:137-143.
12. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
13. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
14. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001;6:80-91.
15. Andrews PL, Naylor RJ, Joss RA. Neuropharmacology of emesis and its relevance to anti-emetic therapy: consensus and controversies. Support Care Cancer 1998;6:197-203.
16. Cichewicz DL. Synergistic interactions between cannabinoids and opioid analgesics. Life Sci 2004;74:1317-1324.
17. Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action. J Pain 2000;1:2-14.
18. Nabilone (Cesamet) Prescribing Information. San Diego, Calif: Valeant Pharmaceuticals International; 2006.
19. Dronabinol (Marinol) Prescribing Information. Marietta, Ga: Solvay Pharmaceuticals, Inc.; 2005.
20. Traimér MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Br Med J 2001;323:1-8.
21. Nahas G, Harvey DJ, Sutin K, et al. A molecular basis of the therapeutic and psychoactive properties of cannabis (delta-9-tetrahydrocannabinol). Prog Neuropsychopharmacol Biol Psychiatry 2002;26:721-730.
22. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21:3205-3265.
23. Noyes R, Brunk SF, Avery DH, Canter A.The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-89.
24. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990;240:397-401.
25. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579.
26. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 2003;362:1517-1526.
27. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669.
28. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 2003;290:1757-1762.
29. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-486.